Journal
DRUGS IN R&D
Volume 13, Issue 4, Pages 289-296Publisher
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1007/s40268-013-0032-6
Keywords
-
Categories
Funding
- Eli Lilly and Company
Ask authors/readers for more resources
Background Many physicians consider platinum-doublet chemotherapy inappropriate for elderly patients, regardless of their medical fitness. Objective This was a retrospective subgroup analysis of data from a multicenter, randomized, phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced, nonsquamous non-small cell lung cancer (NSCLC). Methods Data from elderly patients (aged >= 65 years and >= 70 years) were evaluated using the same statistical methods as those used in patients aged <70 years and qualified intent-to-treat (Q-ITT) populations. The primary objective of the clinical trial was comparison of pemetrexed + carboplatin with docetaxel + carboplatin in terms of survival without grade 3 or 4 toxicity in chemo-naive NSCLC patients. Results The >= 65-and >= 70-year age groups had 68 and 37 patients, respectively. Among patients aged >= 65 years, the adjusted hazard ratio (HR) for survival without grade 3-4 toxicity (HR 0.40, 95 % confidence interval [CI] 0.23-0.70) favored pemetrexed + carboplatin; this was similar to the HRs in patients aged >= 70 years (HR 0.43, 95 % CI 0.20-0.92), patients aged <70 years (HR 0.44, 95 % CI 0.32-0.62), and the Q-ITT population (HR 0.45, 95 % CI 0.34-0.61). The median values for overall survival (OS) and progression-free survival (PFS) were similar across all age-group subsets and the Q-ITT population. The HRs for OS and PFS were similar for all age-group subsets, except for the C70-year age group, which favored pemetrexed + carboplatin to a greater extent. The toxicity profile was similar across age groups, with the exception of diarrhea, mucosal inflammation, and grade 3-4 neutropenia and leukopenia, which were slightly more common in elderly patients in both treatment arms. Between-arm differences in the toxicity profiles for the >= 65-, >= 70-and <70-year age subgroups were similar to those in the Q-ITT population. There were no on-study deaths or unexpected toxicities. Conclusion The benefits of pemetrexed + carboplatin were maintained, and toxicity was manageable in both elderly subgroups. The favorable risk-benefit profile of pemetrexed + carboplatin makes it an appropriate firstline treatment option for elderly patients with advanced nonsquamous NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available